论文部分内容阅读
目的探讨尼莫地平治疗慢性脑供血不足(CCCI)的疗效。方法将110例CCCI患者随机分为两组,各55例。对照组患者采用常规治疗方法(阿司匹林、胞磷酸胆碱、活血化瘀中成药等),治疗组患者在常规治疗基础上加用尼莫地平口服;观察两组患者的临床疗效及治疗前后经颅多普勒超声(TCD)的变化。结果治疗组患者的临床疗效总有效率为78.2%,明显优于对照组的52.7%,差异有统计学意义(P<0.01);两组患者治疗前后TCD比较,治疗组患者的总有效率为76.4%,明显高于对照组的56.4%,差异有统计学意义(P<0.05)。结论尼莫地平治疗CCCI疗效好,安全方便,且价格低廉。
Objective To investigate the efficacy of nimodipine in the treatment of chronic cerebral hypoperfusion (CCCI). Methods 110 patients with CCCI were randomly divided into two groups, each of 55 cases. Patients in the control group were treated with conventional therapy (aspirin, cholinephosphate, Chinese patent medicine for promoting blood circulation and removing blood stasis). The patients in the treatment group were treated with nimodipine orally on the basis of routine treatment. The clinical efficacy and transcranial Doppler ultrasound (TCD) changes. Results The total effective rate of the treatment group was 78.2%, which was significantly better than that of the control group (52.7%, P <0.01). The TCD of the two groups before and after treatment was significantly higher than that of the control group 76.4%, significantly higher than 56.4% of the control group, the difference was statistically significant (P <0.05). Conclusion Nimodipine is effective in treatment of CCCI, safe and convenient, and the price is low.